Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock ...

Zoetis Inc. closed 23.70% below its 52-week high of $200.33, which the company reached on September 19th.

The stock's fall snapped a three-day winning streak.

Zoetis delivered revenue and adjusted EPS above Wall Street expectations in Q1, driven by strong organic operational growth across its diverse portfolio. Management pointed to particularly robust ...

Review quarterly and annual revenue, net income, and cash flow for Zoetis Inc Class A (ZTS:XNYS) stock through the last fiscal year.

Each stock has a return on invested capital between 17% and 27%, showing a strong ability to reinvest in their businesses ...

Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

U.S. equities rose at midday ahead of the latest announcement from the Federal Reserve, as President Donald Trump again ...

Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results , with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance of $9.5 billion at the midpoint ...

Zoetis published its 2024 Sustainability Progress Update" Advancing Sustainability in Animal Health for a Better Future" to highlight the company’ s continued progress toward achieving its ...

Review Zoetis Inc Class A (ZTS:XNYS) stock and the current sustainability and ESG risk rating to help with your investing decisions.